S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
Log in
NASDAQ:GLPG

Galapagos News Headlines

$123.68
+0.58 (+0.47 %)
(As of 10/22/2020 04:30 PM ET)
Add
Compare
Today's Range
$121.42
Now: $123.68
$123.81
50-Day Range
$122.47
MA: $136.52
$148.25
52-Week Range
$112.00
Now: $123.68
$274.03
Volume87,521 shs
Average Volume156,248 shs
Market Capitalization$8.08 billion
P/E Ratio79.28
Dividend YieldN/A
Beta0.8

Headlines

Galapagos (NASDAQ GLPG) News Headlines Today

Source:
DateHeadline
Galapagos (NASDAQ:GLPG) Upgraded at Zacks Investment ResearchGalapagos (NASDAQ:GLPG) Upgraded at Zacks Investment Research
marketbeat.com - October 22 at 12:40 AM
GALAPAGOS NV/S (NASDAQ:GLPG) Downgraded by Jefferies Financial Group to "Hold"GALAPAGOS NV/S (NASDAQ:GLPG) Downgraded by Jefferies Financial Group to "Hold"
marketbeat.com - August 25 at 7:06 AM
GALAPAGOS NV/S (NASDAQ:GLPG) Price Target Cut to $158.00 by Analysts at Morgan StanleyGALAPAGOS NV/S (NASDAQ:GLPG) Price Target Cut to $158.00 by Analysts at Morgan Stanley
marketbeat.com - August 21 at 8:49 AM
Galapagos -6.8% on downgrade by Goldman Sachs - Seeking AlphaGalapagos -6.8% on downgrade by Goldman Sachs - Seeking Alpha
seekingalpha.com - October 21 at 7:01 PM
Galapagos (NASDAQ:GLPG) Stock Rating Lowered by Goldman Sachs GroupGalapagos (NASDAQ:GLPG) Stock Rating Lowered by Goldman Sachs Group
americanbankingnews.com - October 21 at 11:39 AM
Crisis in the Galapagos - Los Angeles TimesCrisis in the Galapagos - Los Angeles Times
latimes.com - October 20 at 11:52 PM
Galapagos Islands threatened by fishing fleets and COVID-19 - Los Angeles TimesGalapagos Islands threatened by fishing fleets and COVID-19 - Los Angeles Times
latimes.com - October 18 at 6:25 PM
Galapagos NV (NASDAQ:GLPG) Sees Significant Growth in Short InterestGalapagos NV (NASDAQ:GLPG) Sees Significant Growth in Short Interest
americanbankingnews.com - October 18 at 4:26 PM
Galapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of BiopharmaGalapagos Knee Osteoarthritis Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 18 at 8:24 AM
Galapagos NV: Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patientsGalapagos NV: Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
finanznachrichten.de - October 17 at 6:59 PM
GALAPAGOS NV/S (NASDAQ:GLPG) Stock Rating Reaffirmed by UBS GroupGALAPAGOS NV/S (NASDAQ:GLPG) Stock Rating Reaffirmed by UBS Group
americanbankingnews.com - October 16 at 4:58 PM
GALAPAGOS NV/S (NASDAQ:GLPG) PT Lowered to $131.00 at Royal Bank of CanadaGALAPAGOS NV/S (NASDAQ:GLPG) PT Lowered to $131.00 at Royal Bank of Canada
americanbankingnews.com - October 16 at 12:09 PM
GALAPAGOS NV/S (NASDAQ:GLPG) Shares Gap Down  on Analyst DowngradeGALAPAGOS NV/S (NASDAQ:GLPG) Shares Gap Down on Analyst Downgrade
americanbankingnews.com - October 16 at 11:31 AM
Correction: Jyseleca®  (filgotinib) approved in Japan for rheumatoid arthritisCorrection: Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
finance.yahoo.com - October 15 at 6:55 PM
Galapagos announces first dosing with Toledo  compound GLPG3970 in psoriasis trialGalapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
finance.yahoo.com - October 15 at 6:55 PM
GALAPAGOS NV/S (NASDAQ:GLPG) Rating Reiterated by BarclaysGALAPAGOS NV/S (NASDAQ:GLPG) Rating Reiterated by Barclays
americanbankingnews.com - October 13 at 3:15 PM
Galapagos NV (GXE.DE)Galapagos NV (GXE.DE)
finance.yahoo.com - October 10 at 7:34 AM
GALAPAGOS NV/S (NASDAQ:GLPG) Given "Neutral" Rating at UBS GroupGALAPAGOS NV/S (NASDAQ:GLPG) Given "Neutral" Rating at UBS Group
americanbankingnews.com - October 8 at 4:07 PM
Galapagos NV: Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trialGalapagos NV: Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
finanznachrichten.de - September 29 at 7:44 PM
Vertex or Galapagos: Which Biotech Stock Does The Street Favor?Vertex or Galapagos: Which Biotech Stock Does The Street Favor?
finance.yahoo.com - September 27 at 12:04 PM
Galapagos increases share capital through subscription right exercisesGalapagos increases share capital through subscription right exercises
finance.yahoo.com - September 18 at 8:49 PM
Galapagos Pops 9% On Positive Result Of Novesa TrialGalapagos Pops 9% On Positive Result Of Novesa Trial
finance.yahoo.com - September 14 at 12:40 PM
Galapagos (GLPG) Surges: Stock Moves 8.8% HigherGalapagos (GLPG) Surges: Stock Moves 8.8% Higher
finance.yahoo.com - September 14 at 12:40 PM
Gilead Just Made a Big Bet on Immunomedics’ Cancer Treatment. Was the Price too High?Gilead Just Made a Big Bet on Immunomedics’ Cancer Treatment. Was the Price too High?
finance.yahoo.com - September 14 at 12:40 PM
The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For ReviewThe Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review
finance.yahoo.com - September 11 at 12:58 PM
Primary endpoint achieved with ziritaxestat   in NOVESA trial in systemic sclerosis patientsPrimary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients
finance.yahoo.com - September 11 at 1:25 AM
Primary endpoint achieved with ziritaxestat   in NOVESA trial in systemic sclerosis patientsPrimary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
benzinga.com - September 10 at 10:51 PM
Galapagos NV: Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society CongressGalapagos NV: Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress
finanznachrichten.de - August 26 at 3:01 PM
StockBeat: Galapagos' Halo SlipsStockBeat: Galapagos' Halo Slips
finance.yahoo.com - August 21 at 7:34 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Galapagos NV (GLPG) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Galapagos NV (GLPG) Investigation
finance.yahoo.com - August 20 at 3:50 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPGSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
finance.yahoo.com - August 19 at 11:49 PM
Galapagos is Now Oversold (GLPG)Galapagos is Now Oversold (GLPG)
nasdaq.com - August 19 at 1:48 PM
Two Surprising FDA Rejections Raise Alarms for Biotech InvestorsTwo Surprising FDA Rejections Raise Alarms for Biotech Investors
finance.yahoo.com - August 19 at 1:48 PM
Why Galapagos Stock Is Crashing TodayWhy Galapagos Stock Is Crashing Today
finance.yahoo.com - August 19 at 1:48 PM
Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritisGalapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis
finance.yahoo.com - August 18 at 7:46 PM
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel diseaseScipher Medicine and Galapagos sign collaboration in inflammatory bowel disease
benzinga.com - August 12 at 4:11 PM
Galapagos NV (GLPG) Q2 2020 Earnings Call TranscriptGalapagos NV (GLPG) Q2 2020 Earnings Call Transcript
fool.com - August 8 at 5:09 AM
Galapagos NVs (GLPG) CEO Onno van de Stolpe on Q2 2020 Results - Earnings Call TranscriptGalapagos NV's (GLPG) CEO Onno van de Stolpe on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 2:30 PM
Galapagos reports solid H1 2020 progressGalapagos reports solid H1 2020 progress
finance.yahoo.com - August 6 at 6:26 PM
GILEAD  AND  GALAPAGOS  ANNOUNCE  POSITIVE  EUROPEAN  CHMP  OPINION  FOR  JYSELECA®  (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE  RHEUMATOID  ARTHRITISGILEAD  AND  GALAPAGOS  ANNOUNCE  POSITIVE  EUROPEAN  CHMP  OPINION  FOR  JYSELECA®  (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO  SEVERE  RHEUMATOID  ARTHRITIS
finance.yahoo.com - July 24 at 10:07 AM
GLPG Crosses Below Key Moving Average LevelGLPG Crosses Below Key Moving Average Level
www.nasdaq.com - June 26 at 2:18 PM
Hedge Funds Are Warming Up To Galapagos NV (GLPG)Hedge Funds Are Warming Up To Galapagos NV (GLPG)
finance.yahoo.com - June 26 at 2:18 PM
GLPG.BE - Galapagos NV Profile | ReutersGLPG.BE - Galapagos NV Profile | Reuters
www.reuters.com - June 17 at 3:06 PM
AstraZeneca Ponders a Huge $240 Billion Gilead GambleAstraZeneca Ponders a Huge $240 Billion Gilead Gamble
finance.yahoo.com - June 7 at 1:52 PM
New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic ArthritisNew Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis
finance.yahoo.com - June 5 at 5:32 PM
Galapagos NV: Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid ArthritisGalapagos NV: Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
www.finanznachrichten.de - June 5 at 12:28 PM
Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib ResultsGalapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib Results
finance.yahoo.com - May 21 at 2:14 PM
Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis TrialGilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial
finance.yahoo.com - May 21 at 4:12 AM
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative ColitisGilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
finance.yahoo.com - May 20 at 6:11 PM
Galapagos NV: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic PulmonaryGalapagos NV: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary
www.bloomberg.com - May 11 at 11:18 PM
H.C. Wainwright Sticks to Their Buy Rating for Galapagos NVH.C. Wainwright Sticks to Their Buy Rating for Galapagos NV
finance.yahoo.com - May 11 at 6:17 PM
Galapagos NV (GLPG) Q1 2020 Earnings Call TranscriptGalapagos NV (GLPG) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 9 at 10:21 PM
Galapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2020 Results - Earnings Call TranscriptGalapagos NV (GLPG) CEO Onno van de Stolpe on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:20 PM
This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.